Glick, Gary,Ghosh, Shomir,Roush, William R.,Olhava, Edward James,O'malley, Daniel
申请号：
AU2018221076
公开号：
AU2018221076A1
申请日:
2018.02.16
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/ or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
